Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Effect of Adrenomedullin on Migraine-like Attacks in Patients With Migraine: A Randomized Crossover Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Enterovirus Meningitis in Adults: A Prospective Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 7T Epilepsy Task Force Consensus Recommendations on the Use of 7T MRI in Clinical Practice

    Research output: Contribution to journalReviewpeer-review

  3. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Global Impact of COVID-19 on Stroke Care and Intravenous Thrombolysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The chronobiology of migraine: a systematic review

    Research output: Contribution to journalReviewpeer-review

  2. Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity

    Research output: Contribution to journalReviewpeer-review

  3. Timing and durability of response to erenumab in patients with chronic migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

ObjectiveTo determine whether the intravenous infusion of adrenomedullin, a potent vasodilator belonging to calcitonin family of peptides, provokes attacks of migraine in patients.MethodsTwenty migraine without aura patients participated in a placebo-controlled and double-blinded clinical study. In a randomized and crossover design the patients received an intravenous infusion of human adrenomedullin (19.9 picomole/kg/min) or placebo (saline) administrated via an automated intravenous pump (20 minutes). The patients participated in two study days with washout period of minimum of seven days. The primary outcome of the study was predefined as a difference in migraine incidence (0-12 h) and the secondary outcome were the headache intensity score's area under curve (AUC0-12 h) and the (AUC 0-90 min) for MAP, flushing and HR.ResultsEleven migraine without aura patients (55%) fulfilled migraine attacks criteria after adrenomedullin infusion in comparison to only three patients reported attack (15%) after placebo (P= 0.039). We found that patients reported in a period of (0-12 hours) stronger headache intensity after adrenomedullin in comparison to placebo infusion (P= 0.035). AUC0-90 min for HR and, flushing (P < 0.05) were significant and MAP (P = 0.502) remain unchanged. Common adverse events reported were facial flushing, heat sensation and palpitation (P <0.001)ConclusionOur data implicate adrenomedullin in migraine pathogenesis. This suggests that adrenomedullin and/or its receptors are novel therapeutic targets for the treatment of migraine. However, we cannot discount for the possibility that adrenomedullin may be acting through the canonical CGRP receptor.

Original languageEnglish
JournalNeurology
Volume96
Issue number20
Pages (from-to)e2488-e2499
ISSN0028-3878
DOIs
Publication statusPublished - 18 May 2021

ID: 65607481